AbbVie could be heading for its second acquisition in the space of a month, with reports emerging of late-stage negotiations with Gilgamesh Pharmaceuticals, a central nervous system (CNS) drug ...

Less than a month after reports of takeover talks between AbbVie and Gilgamesh Pharma first emerged, the pair have gone public with details of a $1.2 billion deal – but it is not an acquisition. It ...

White House responds to Spain closing airspace to US military Dietitians say you shouldn't take these vitamins in the morning Country artist sounds alarm on California's decline New bodycam footage of ...

AbbVie will pay up to US$1.2 billion to acquire Gilgamesh’s short-acting psychedelic bretisilocin, highlighting growing industry interest in hallucinogenic drugs for the treatment of psychiatric ...

Gilgamesh Brewing started in 2009 by three brothers and their father in Turner. They opened their first restaurant and pub in 2012 in southeast Salem. From 2019 to 2024, they opened three more ...

AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.2bn, including an upfront payment and development milestones.

AbbVie (NYSE:ABBV) has agreed to acquire from Gilgamesh Pharmaceuticals its lead investigational candidate, Bretisilocin, for up to $1.2 billion. The deal includes upfront payment plus development ...

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is ...

NORTH CHICAGO, Ill. and NEW YORK, Aug. 25, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ("Gilgamesh") today announced a definitive agreement under which AbbVie will ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. AbbVie on Monday said it ...

In another deal between the two companies that could be worth more than $1 billion, Abbvie Inc. is buying Gilgamesh Pharmaceuticals Inc.’s lead candidate bretisilocin (GM-2505) for up to $1.2 billion, ...